FDA Approved: ALYFTREK — Supplemental Application (Vertex Pharmaceuticals Incorporated)

View source ↗

Summary

The FDA approved a supplemental application for ALYFTREK (a triple combination of vanzacaftor, tezacaftor, and deutivacaftor) from Vertex Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)

Snippet

SUPPL AP for ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)